SARS-CoV-2

Disease

Related News

Researchers Develop New Methods for Chiral Sulfur Compounds with Antiviral Potential

Two research teams have developed catalytic methods for synthesizing chiral sulfur compounds with antiviral potential. One approach uses an organocatalytic strategy to create vinyl sulfinamides that bind to SARS-CoV-2 and HIV-1 proteins, while another employs copper catalysis for high-yield production of chiral sulfilimines. Both methods address critical gaps in accessing valuable chemical space for drug discovery.

Related Clinical Trials

NCT ID Title Status Phase
NCT07387211

Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region

COMPLETED NA
NCT07266558

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

ACTIVE_NOT_RECRUITING PHASE4
NCT06864143

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

COMPLETED PHASE2
NCT06743334

Secondary Databased Post-marketing Surveillance Study of BNT162b2

COMPLETED
NCT06689423

Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay

COMPLETED
NCT06684379

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

RECRUITING PHASE1/PHASE2
NCT06610643

Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients

NOT_YET_RECRUITING NA
NCT06585241

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

RECRUITING PHASE4
NCT06508320

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

COMPLETED PHASE2
NCT06489860

SARS-CoV-2 Safety Study for the Treatment of COVID-19

WITHDRAWN PHASE2